Carneiro, B. A., Safran, H., Beck, J. T. T., Hamid, O., Spira, A. I., Savvides, P., … Santana-Davila, R. (2023). Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naive advanced solid tumors. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Carneiro, Benedito A., Howard Safran, J Thaddeus Thaddeus Beck, Omid Hamid, Alexander I. Spira, Panos Savvides, Martin Gutierrez, et al. “Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naive advanced solid tumors.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Carneiro BA, Safran H, Beck JTT, Hamid O, Spira AI, Savvides P, et al. Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naive advanced solid tumors. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Carneiro, Benedito A., et al. “Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naive advanced solid tumors.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Carneiro BA, Safran H, Beck JTT, Hamid O, Spira AI, Savvides P, Gutierrez M, Zhao Y, Abbruzzese JL, Ward JP, Weroha SJ, Harris LD, Kent S, Pierceall W, Skoura A, Zheng J, Kern KA, Thomas JS, Santana-Davila R. Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naive advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY. 2023.